atezolizumab plus bevacizumab (n=334) vs. Standard of Care (SoC) (n=334)
randomized controlled trial
atezolizumab plus bevacizumab
1200 mg intravenous atezolizumab plus intravenous bevacizumab 15 mg/kg every 3 weeks for up to 12 months or 17 cycles
active surveillance
Patients randomly allocated to active surveillance were permitted to receive crossover treatment with atezolizumab plus bevacizumabat investigator discretion on independent review facility confirmation of disease recurrence. Resection or ablation of recurrent lesions was allowed before crossover treatment.